{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:01:08Z","timestamp":1790208068644,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007682","name":"Medicinski Fakultet, Sveu\u010dili\u0161te u Zagrebu","doi-asserted-by":"publisher","award":["1118002 and 1119002"],"award-info":[{"award-number":["1118002 and 1119002"]}],"id":[{"id":"10.13039\/501100007682","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00277-020-04353-3","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T16:11:11Z","timestamp":1605888671000},"page":"1517-1524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5850-180X","authenticated-orcid":false,"given":"Sandra","family":"Ba\u0161i\u0107-Kinda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-1641","authenticated-orcid":false,"given":"Ivo","family":"Radman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6298-1540","authenticated-orcid":false,"given":"Dino","family":"Dujmovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1988-6684","authenticated-orcid":false,"given":"Ivana","family":"Ili\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Kralik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareta","family":"Dobreni\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2840-5734","authenticated-orcid":false,"given":"Lea","family":"Galuni\u0107-Bili\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavle","family":"Ron\u010devi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-7358","authenticated-orcid":false,"given":"Marijo","family":"Vodanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4534-4283","authenticated-orcid":false,"given":"Zrinka","family":"Serti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5527-0647","authenticated-orcid":false,"given":"Ida","family":"Hude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-4277","authenticated-orcid":false,"given":"Igor","family":"Aurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"4353_CR1","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.25460","volume":"94","author":"Y Liu","year":"2019","unstructured":"Liu Y, Barta SK (2019) Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol 94:604\u2013616. https:\/\/doi.org\/10.1002\/ajh.25460","journal-title":"Am J Hematol"},{"key":"4353_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1182\/asheducation-2017.1.284","volume":"2017","author":"A Davies","year":"2017","unstructured":"Davies A (2017) Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently? Hematology 2017:284\u2013294. https:\/\/doi.org\/10.1182\/asheducation-2017.1.284","journal-title":"Hematology"},{"key":"4353_CR3","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, Andr\u00e9 M, Johnson PW, Pfreundschuh M, Ladetto M, ESMO Guidelines Committee (2015) Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v116\u2013v125. https:\/\/doi.org\/10.1093\/annonc\/mdv304","journal-title":"Ann Oncol"},{"key":"4353_CR4","unstructured":"National Comprehensive Cancer Network (2018) B-cell lymphomas (version 2.2018). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed 22 Apr 2020"},{"key":"4353_CR5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, R\u00fcbe C, Loeffler M, German High-Grade Non-Hodgkin's Lymphoma Study Group (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626\u2013633. https:\/\/doi.org\/10.1182\/blood-2003-06-2094","journal-title":"Blood"},{"key":"4353_CR6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Tr\u00fcmper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, L\u00f3pez-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera International Trial (MInT) Group (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12:1013\u20131022. https:\/\/doi.org\/10.1016\/S1470-2045(11)70235-2","journal-title":"Lancet Oncol"},{"key":"4353_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1385\/MO:23:2:283","volume":"23","author":"M Adde","year":"2006","unstructured":"Adde M, Enblad G, Hagberg H, Sundstr\u00f6m C, Laurell A (2006) Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14). Med Oncol 23:283\u2013294. https:\/\/doi.org\/10.1385\/MO:23:2:283","journal-title":"Med Oncol"},{"key":"4353_CR8","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","volume":"13","author":"N Schmitz","year":"2012","unstructured":"Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B, German High-Grade Lymphoma Study Group (DSHNHL) (2012) Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 13:1250\u20131259. https:\/\/doi.org\/10.1016\/S1470-2045(12)70481-3","journal-title":"Lancet Oncol"},{"key":"4353_CR9","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/annonc\/mds621","volume":"24","author":"H Holte","year":"2013","unstructured":"Holte H, Lepp\u00e4 S, Bj\u00f6rkholm M, Fluge \u00d8, Jyrkki\u00f6 S, Delabie J, Sundstr\u00f6m C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Foss\u00e5 A, \u00d8stenstad B, L\u00f6fvenberg E, Nordstr\u00f6m M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M (2013) Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell\/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol 24:1385\u20131392. https:\/\/doi.org\/10.1093\/annonc\/mds621","journal-title":"Ann Oncol"},{"key":"4353_CR10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bjh.15710","volume":"184","author":"B Friedrichs","year":"2019","unstructured":"Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Haenel M, Viardot A, Schmidt C, Ruebe C, Loeffler M, Pfreundschuh M, Rosenwald A, Glass B, Lenz G, Schmitz N, for the German high-grade lymphoma Study Group (2019) Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial. Br J Haematol 184:760\u2013768. https:\/\/doi.org\/10.1111\/bjh.15710","journal-title":"Br J Haematol"},{"key":"4353_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/annonc\/mdr058","volume":"23","author":"AO Gang","year":"2012","unstructured":"Gang AO, Str\u00f8m C, Pedersen M, d\u2019Amore F, Pedersen LM, Bukh A, Pedersen BB, Moeller MB, Mortensen LS, Gadeberg OV, Ingeberg S, Mourits-Andersen T, Pulczynski S, Brown PN (2012) R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Ann Oncol 23:147\u2013153. https:\/\/doi.org\/10.1093\/annonc\/mdr058","journal-title":"Ann Oncol"},{"key":"4353_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjh.14399","volume":"175","author":"CM Mel\u00e9n","year":"2016","unstructured":"Mel\u00e9n CM, Enblad G, Sonnevi K, Junl\u00e9n HR, Smedby KE, Jerkeman M, Wahlin BE (2016) Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. Br J Haematol 175:614\u2013622. https:\/\/doi.org\/10.1111\/bjh.14399","journal-title":"Br J Haematol"},{"key":"4353_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/hon.2256","volume":"35","author":"T W\u00e4sterlid","year":"2017","unstructured":"W\u00e4sterlid T, Hartman L, Sz\u00e9kely E, Jerkeman M (2017) Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. Hematol Oncol 35:151\u2013157. https:\/\/doi.org\/10.1002\/hon.2256","journal-title":"Hematol Oncol"},{"key":"4353_CR14","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1182\/bloodadvances.2020001518","volume":"4","author":"S Lepp\u00e4","year":"2020","unstructured":"Lepp\u00e4 S, J\u00f8rgensen J, Tierens A, Meriranta L, \u00d8stlie I, de Nully Brown P, Fagerli UM, Larsen TS, Mannisto S, Munksgaard L, Maisenh\u00f6lder M, Vasala K, Meyer P, Jerkeman M, Bj\u00f6rkholm M, Fluge \u00d8, Jyrkki\u00f6 S, Liest\u00f8l K, Ralfkiaer E, Spetalen S, Beiske K, Karjalainen-Lindsberg ML, Holte H (2020) Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Adv 4:1906\u20131915. https:\/\/doi.org\/10.1182\/bloodadvances.2020001518","journal-title":"Blood Adv"},{"key":"4353_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275\u2013282. https:\/\/doi.org\/10.1182\/blood-2003-05-1545","journal-title":"Blood"},{"key":"4353_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"4353_CR17","unstructured":"National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 5 Apr 2020"},{"key":"4353_CR18","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/JCO.18.01994","volume":"37","author":"NL Bartlett","year":"2019","unstructured":"Bartlett NL, Wilson WH, Jung S-H, Hsi ED, Maurer MJ, Pederson LD, Polley MYC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Sch\u00f6der H, Zelenetz AD, Leonard JP (2019) Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance\/CALGB 50303. J Clin Oncol 37:1790\u20131799. https:\/\/doi.org\/10.1200\/JCO.18.01994","journal-title":"J Clin Oncol"},{"key":"4353_CR19","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","volume":"378","author":"C R\u00e9cher","year":"2011","unstructured":"R\u00e9cher C, Coiffier B, Haioun C, Molina TJ, Ferm\u00e9 C, Casasnovas O, Thi\u00e9blemont C, Bosly A, Laurent G, Morschhauser F, Ghesqui\u00e8res H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H (2011) Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 378:1858\u20131867. https:\/\/doi.org\/10.1016\/S0140-6736(11)61040-4","journal-title":"Lancet"},{"key":"4353_CR20","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","volume":"368","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368:1408\u20131416. https:\/\/doi.org\/10.1056\/NEJMoa1214561","journal-title":"N Engl J Med"},{"key":"4353_CR21","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1002\/cam4.2347","volume":"8","author":"EHL Chan","year":"2019","unstructured":"Chan EHL, Koh LP, Lee J, de Mel S, Jeyasekharan A, Liu X, Tang T, Lim ST, Tao M, Quek R, Farid Bin Harunal Ras M, Lee YS, Diong C, Tan D, Kim SJ, Chee YL, Poon LMM (2019) Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma. Cancer Med 8:4626\u20134632. https:\/\/doi.org\/10.1002\/cam4.2347","journal-title":"Cancer Med"},{"key":"4353_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ejh.13337","volume":"104","author":"A Malenda","year":"2020","unstructured":"Malenda A, Ko\u0142kowska-Le\u015bniak A, Pu\u0142a B, D\u0142ugosz-Danecka M, Che\u0142stowska M, Ko\u0144ska A, Giza A, Lech-Mara\u0144da E, Jurczak W, Warzocha K (2020) Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma. Eur J Haematol 104:59\u201366. https:\/\/doi.org\/10.1111\/ejh.13337","journal-title":"Eur J Haematol"},{"key":"4353_CR23","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, Belada D, Samoilova O, Suh C, Lepp\u00e4 S, Rai S, Turgut M, Jurczak W, Cheung MC, Gurion R, Yeh SP, Lopez-Hernandez A, D\u00fchrsen U, Thieblemont C, Chiattone CS, Balasubramanian S, Carey J, Liu G, Shreeve SM, Sun S, Zhuang SH, Vermeulen J, Staudt LM, Wilson W, on behalf of the PHOENIX investigators (2019) Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non\u2013germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 37:1285\u20131295. https:\/\/doi.org\/10.1200\/JCO.18.02403","journal-title":"J Clin Oncol"},{"key":"4353_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","volume":"33","author":"GS Nowakowski","year":"2015","unstructured":"Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE (2015) Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non\u2013germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol 33:251\u2013257. https:\/\/doi.org\/10.1200\/JCO.2014.55.5714","journal-title":"J Clin Oncol"},{"key":"4353_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Tr\u00fcmper L, \u00d6sterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379\u2013391. https:\/\/doi.org\/10.1016\/S1470-2045(06)70664-7","journal-title":"Lancet Oncol"},{"key":"4353_CR26","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381:1817\u20131826. https:\/\/doi.org\/10.1016\/S0140-6736(13)60313-X","journal-title":"Lancet"},{"key":"4353_CR27","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2016.67.2980","volume":"34","author":"S Cortelazzo","year":"2016","unstructured":"Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, di Nicola M, Patti C, Mul\u00e9 A, Zanni M, Zoli V, Billio A, Piccin A, Negri G, Castellino C, di Raimondo F, Ferreri AJM, Benedetti F, la Nasa G, Gini G, Trentin L, Frezzato M, Flenghi L, Falorio S, Chilosi M, Bruna R, Tabanelli V, Pileri S, Masciulli A, Delaini F, Boschini C, Rambaldi A (2016) Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas. J Clin Oncol 34:4015\u20134022. https:\/\/doi.org\/10.1200\/JCO.2016.67.2980","journal-title":"J Clin Oncol"},{"key":"4353_CR28","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S1470-2045(17)30444-8","volume":"18","author":"A Chiappella","year":"2017","unstructured":"Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U (2017) Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol 18:1076\u20131088. https:\/\/doi.org\/10.1016\/S1470-2045(17)30444-8","journal-title":"Lancet Oncol"},{"key":"4353_CR29","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood-2018-99-116845","volume":"132","author":"LH Sehn","year":"2018","unstructured":"Sehn LH, Congiu AG, Culligan DJ et al (2018) No added benefit of eight versus six cycles of CHOP when combined with rituximab in previously untreated diffuse large B-cell lymphoma patients: results from the international phase III GOYA study. Blood 132:783. (abstract). https:\/\/doi.org\/10.1182\/blood-2018-99-116845","journal-title":"Blood"},{"key":"4353_CR30","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/bjh.15603","volume":"183","author":"J Baech","year":"2018","unstructured":"Baech J, Hansen SM, Lund PE, Soegaard P, Brown PN, Haaber J, J\u00f8rgensen J, Starklint J, Josefsson P, Poulsen CB, Juul MB, Torp-Pedersen C, el-Galaly TC (2018) Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines. Br J Haematol 183:717\u2013726. https:\/\/doi.org\/10.1111\/bjh.15603","journal-title":"Br J Haematol"},{"key":"4353_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.17179\/excli2015-561","volume":"14","author":"A Montecucco","year":"2015","unstructured":"Montecucco A, Zanetta F, Biamonti G (2015) Molecular mechanisms of etoposide. EXCLI J 14:95\u2013108. https:\/\/doi.org\/10.17179\/excli2015-561","journal-title":"EXCLI J"},{"key":"4353_CR32","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21:440\u2013446. https:\/\/doi.org\/10.1097\/FPC.0b013e32833ffb56","journal-title":"Pharmacogenet Genomics"},{"key":"4353_CR33","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00204-018-2170-7","volume":"92","author":"H Nemade","year":"2018","unstructured":"Nemade H, Chaudhari U, Acharya A et al (2018) Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells. Arch Toxicol 92:1507\u20131524. https:\/\/doi.org\/10.1007\/s00204-018-2170-7","journal-title":"Arch Toxicol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04353-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04353-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04353-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T06:14:52Z","timestamp":1620800092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04353-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["4353"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04353-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"25 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional ethical committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all patients included in this analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}